Hyaluronidase Power Injection Market Outlook:
Hyaluronidase Power Injection Market size was over USD 1.07 billion in 2025 and is poised to exceed USD 2.6 billion by 2035, witnessing over 9.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of hyaluronidase power injection is estimated at USD 1.16 billion.
The increasing acuteness across different application fields will act as the primary driver that will drive the market of hyaluronidase power injection and will take it to the anticipated CAGR. For instance, the degradation kinetics of the TEOSYAL RHA accumulation, manufactured by TEOXANE SA (Geneva, Switzerland), is implementing the maintained network technology (PNT) to use in different applications. In humans, six different hyaluronidases, HYAL1-4, HYAL-P1, and PH-20, have been identified. Hyaluronidase looks for applications in cosmetic therapies, cancer treatment, and ophthalmic therapeutic solutions.
Additionally, the increasing number of nominally invasive aesthetic surgeries is calculated to amplify the hyaluronidase power injection system's demand in the forecast period. For instance, The International Society of Aesthetic Plastic Surgery (ISAPS) announced the results of its yearly Global Survey on Aesthetic/Cosmetic Procedures this week at the ISAPS Olympiad Athens World Congress 2023, which rounded up more than 1,000 attendees from 90 countries to talk about the newest scientific research, novelties, and processes to modify patient protection in aesthetic plastic surgery. The report demonstrates an 11.2% complete rise in techniques executed by plastic surgeons in 2022 with more than 14.9 million surgical and 18.8 million non-surgical techniques executed across the world. Liposuction was the most general surgical technique in 2022 as in 2021, with more than 2.3 million techniques and a 21.1% rise.
